Recent research have focused on the intersection of GLP|GIP|GCGR activator therapies and dopamine neurotransmission. While GCGR activators are widely employed for managing type 2 diabetes, their emerging consequences https://joshbocc410010.prublogger.com/40247477/emerging-gcgr-agonists-and-dopamine-modulation-a-comparative-overview